Hard to say whether this will have a material change to revenues. Per the 2022 annual report, Hizentra sales were up 20% during 2022 and is the market leading product for subcutaneous immunoglobulin products.
Page 15 of the annual report shows that patients have a preference for Hizentra for at home dosing, so the pre-filled syringe is an obvious move to make.
Appears to not be all upside as this has lead to a decline in Privigen sales.
DYOR, IMO, blah blah
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$267.92 |
Change
-1.640(0.61%) |
Mkt cap ! $129.7B | |||
| Open | High | Low | Value | Volume |
| $269.56 | $270.42 | $267.15 | $252.9M | 957.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 879 | $267.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $268.98 | 120 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |